PTPRC and neoplasm: A dose-dependent increase in PD-L1 expression was observed with Mit-A treatment in vitro for tumor biopsies (data not shown) which reflected in the increased PD-L1 expression in the CD45- tumor cells from tumor-bearing mice treated with Mit-A, thus demonstrating the capacity of Mit-A to sensitize orthotopic tumor cells for improved checkpoint blocking therapy.